Sugi Predict

Sugi Predict / Compounds / SCHEMBL1880679

SCHEMBL1880679

SCHEMBL1880679

OCCCc1cccc2[nH]ccc12

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ AHR P35869 1/20 0.44
▸ GLS O94925 2/20 0.43
▸ DAO P14920 1/20 0.42
▸ SLC6A4 P31645 3/20 0.42
▸ HTR1A P08908 2/20 0.42
▸ PIK3CD O00329 1/20 0.41
▸ HDAC1 Q13547 3/20 0.40
▸ HDAC2 Q92769 3/20 0.40
▸ HDAC6 Q9UBN7 2/20 0.40
▸ KDM4E B2RXH2 1/20 0.40
▸ POLB P06746 1/20 0.40
▸ PARP1 P09874 1/20 0.40
▸ MAPK1 P28482 1/20 0.39
▸ BCHE P06276 1/20 0.39
▸ MAPK14 Q16539 1/20 0.38
▸ HDAC3 O15379 1/20 0.38
▸ HDAC4 P56524 1/20 0.38
▸ HDAC7 Q8WUI4 1/20 0.38
▸ HDAC10 Q969S8 1/20 0.38
▸ HDAC11 Q96DB2 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11032690 0.95 GLS (0.45) AHRGLSDAOSLC6A4HTR1A
SCHEMBL6536568 0.89 AHR (0.47) AHRGLSDAOSLC6A4HTR1A
SCHEMBL10565558 0.83 SLC6A4 (0.44) AHRGLSDAOSLC6A4HTR1A
SCHEMBL1962511 0.82 AHR (0.44) AHRGLSDAOSLC6A4HTR1A
SCHEMBL3792774 0.82 AHR (0.44) AHRGLSDAOSLC6A4HTR1A
SCHEMBL28264220 0.82 MPO (0.47) AHRGLSDAOSLC6A4HTR1A
SCHEMBL951816 0.81 AHR (0.50) AHRGLSDAOSLC6A4HTR1A
SCHEMBL30065739 0.81 AHR (0.50) AHRGLSDAOSLC6A4HTR1A
SCHEMBL10970004 0.81 AHR (0.47) AHRGLSDAOSLC6A4HTR1A
SCHEMBL8655960 0.81 MPO (0.46) AHRGLSDAOSLC6A4HTR1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 55 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-103517703-B Stain and application thereof 天野酶制品株式会社 2016-11-09 — — CN claimed
EP-2623093-B1 DYE FOR KERATIN FIBERS USING BILIRUBIN OXIDASE AND INDOLE DERIVATIVES AMANO ENZYME INC (JP) 2016-05-25 — — EP claimed
CN-103998016-B Employ the dyeing of the keratin fiber of indole analog AMANO ENZYME INC. (JP) 2015-09-16 — — CN claimed
US-20140359950-A1 DYEING OF KERATIN FIBERS USING INDOLE ANALOGUE AMANO ENZYME INC. (JP) 2014-12-11 — — US claimed
US-12012411-B2 Viral replication inhibitors KATHOLIEKE UNIVERSITEIT LEUVEN (BE) 2024-06-18 — — US disclosed
US-20220106321-A1 VIRAL REPLICATION INHIBITORS KATHOLIEKE UNIVERSITEIT LEUVEN (BE) 2022-04-07 — — US disclosed
US-11279704-B2 Viral replication inhibitors KATHOLIEKE UNIVERSITEIT LEUVEN (BE) 2022-03-22 — — US disclosed
CN-108440370-B Inhibitors of viral replication 鲁汶天主教大学 2021-07-30 — — CN disclosed
EP-3617192-A1 VIRAL REPLICATION INHIBITORS Katholieke Universiteit Leuven K.U. Leuven R&D (BE) 2020-03-04 — — EP disclosed
US-10550123-B2 Viral replication inhibitors KATHOLIEKE UNIVERSITEIT LEUVEN, K.U. LEUVEN R&D (BE) 2020-02-04 — — US disclosed
US-20190337954-A1 VIRAL REPLICATION INHIBITORS KATHOLIEKE UNIVERSITEIT LEUVEN, K.U. LEUVEN R&D (BE) 2019-11-07 — — US disclosed
EP-2760831-B1 VIRAL REPLICATION INHIBITORS UNIV LEUVEN KATH (BE) 2019-08-07 — — EP disclosed
EP-0814084-B1 Indole derivative as 5-HT1A antagonist and as inhibitor of serotonine reuptake LILLY CO ELI (US) 2001-08-08 — — EP disclosed
WO-2001000144-A2 HAIR COMPOSITION COMPRISING AN OXIDASE AND CYCLODEXTRIN LION CORPORATION (JP) 2001-01-04 — — WO disclosed
US-5912256-A 0-(4-INDOLYLOXY)-3-(4-HYDROXY-4-NAPHTHYLPIPERIDIN-1-YL)PROPANE S ELI LILLY AND COMPANY (US) 1999-06-15 — — US disclosed
EP-0814084-A1 Indole derivatives as 5-HT1A antagonists and as inhibitors of serotonine reuptake ELI LILLY AND COMPANY (US) 1997-12-29 — — EP disclosed
WO-1997048698-A1 COMPOUNDS HAVING EFFECTS ON SEROTONIN-RELATED SYSTEMS ELI LILLY AND COMPANY (US) 1997-12-24 — — WO disclosed
EP-0201400-B1 4-PHENYL PROPYL INDOLE DERIVATIVES AND THEIR SALTS, PROCESS FOR THEIR PREPARATION, THEIR USE AS MEDICINES AND COMPOSITIONS CONTAINING THEM ROUSSEL-UCLAF (FR) 1989-07-19 — — EP disclosed
EP-0201400-A1 4-Phenyl propyl indole derivatives and their salts, process for their preparation, their use as medicines and compositions containing them ROUSSEL-UCLAF (FR) 1986-12-17 — — EP disclosed
EP-0164633-A2 Indole derivatives MERCK PATENT GmbH (DE) 1985-12-18 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11279704-B2 Viral replication inhibitors EIF2AK2, MAVS, ZC3HAV1 AHR 4398/4885GLS 1859/4885DAO 2554/4885
US-20190337954-A1 VIRAL REPLICATION INHIBITORS EIF2AK2, MAVS, ZC3HAV1 AHR 4398/4885GLS 1859/4885DAO 2554/4885
US-10550123-B2 Viral replication inhibitors EIF2AK2, MAVS, ZC3HAV1 AHR 4398/4885GLS 1859/4885DAO 2554/4885
US-20220106321-A1 VIRAL REPLICATION INHIBITORS EIF2AK2, MAVS, ZC3HAV1 AHR 4398/4885GLS 1859/4885DAO 2554/4885
US-12012411-B2 Viral replication inhibitors EIF2AK2, MAVS, ZC3HAV1 AHR 4398/4885GLS 1859/4885DAO 2554/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.